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Research Article
IRRITABLE MOOD IN ADULT MAJOR DEPRESSIVE
DISORDER: RESULTS FROM THEWORLD MENTAL
HEALTH SURVEYS
Viviane Kovess-Masfety, M.D., Ph.D.,1∗ Jordi Alonso, M.D., Ph.D.,2 Matthias Angermeyer, M.D.,3
Evelyn Bromet, Ph.D.,4 Giovanni de Girolamo, M.D.,5 Peter de Jonge, Ph.D.,6 Koen Demyttenaere, M.D.,
Ph.D.,7 Silvia E. Florescu, M.D., Ph.D.,8 Michael J. Gruber, M.S.,9 Oye Gureje, M.D., Ph.D., F.R.C.Psych.,10
Chiyi Hu, M.D., Ph.D.,11 Yueqin Huang, M.D., M.P.H., Ph.D.,12 Elie G. Karam, M.D.,13 Robert Jin, M.A.,14
Jean-Pierre Le´pine, M.D.,15 Daphna Levinson, Ph.D.,16 Katie A. McLaughlin, Ph.D.,17 Marı´a E. Medina-Mora,
Ph.D.,18 Siobhan O’Neill, Ph.D.,19 Yutaka Ono, M.D., Ph.D.,20 Jose´ A. Posada-Villa, M.D.,21 Nancy A.
Sampson, B.A.,9 Kate M. Scott, Ph.D.,22 Victoria Shahly, Ph.D.,9 Dan J. Stein, M.D., Ph.D.,23 Maria C. Viana,
M.D., Ph.D.,24 Zahari Zarkov, M.D.,25 and Ronald C. Kessler, Ph.D.9
Background: Although irritability is a core symptom of DSM-IV major depres-
sive disorder (MDD) for youth but not adults, clinical studies find comparable
rates of irritability between nonbipolar depressed adults and youth. Including
irritability as a core symptom of adult MDD would allow detection of depression-
equivalent syndromes with primary irritability hypothesized to be more common
among males than females. We carried out a preliminary examination of this
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issue using cross-national community-based survey data from 21 countries in
the World Mental Health (WMH) Surveys (n = 110,729). Methods: The as-
sessment of MDD in the WHO Composite International Diagnostic Interview
includes one question about persistent irritability. We examined two expansions
of the definition of MDD involving this question: (1) cases with dysphoria and/or
anhedonia and exactly four of nine Criterion A symptoms plus irritability; and
(2) cases with two or more weeks of irritability plus four or more other Criterion
A MDD symptoms in the absence of dysphoria or anhedonia. Results: Adding
irritability as a tenth Criterion A symptom increased lifetime prevalence by 0.4%
(from 11.2 to 11.6%). Adding episodes of persistent irritability increased preva-
lence by an additional 0.2%. Proportional prevalence increases were significantly
higher, but nonetheless small, among males compared to females. Rates of severe
role impairment were significantly lower among respondents with this irrita-
ble depression who did not meet conventional DSM-IV criteria than those with
DSM-IV MDD. Conclusion: Although limited by the superficial assessment in
this single question on irritability, results do not support expanding adult MDD
criteria to include irritable mood. Depression and Anxiety 30:395–406, 2013.
C© 2013 Wiley Periodicals, Inc.
Key words: epidemiology; depression; mood disorders; assessment/diagnosis;
measurement/psychometrics; irritability; major depression; nosology; worldmen-
tal health (WMH) surveys
INTRODUCTION
The diagnostic signiﬁcance of irritable mood in adult
major depression remains unclear. While childhood–
adolescent irritability is accepted as an equivalent to dys-
phoria and anhedonia in diagnosing pediatric DSM-IV
major depressive disorder (MDD), irritability is not in-
cluded among the criteria of adult MDD. Yet, clinical
studies show irritability to be more common among de-
pressed than nondepressed patients,[1] to be at least as
common in adult as pediatric MDD,[2,3] and to load on
the same factor as other core symptoms of depression
in factor analyses of adult depressive symptoms.[4] This
age-based diagnostic inconsistency is grounded in de-
velopmental notions about the more limited expressive
capacities of youth than adults[4] and in clinical concerns
that adult, but not child–adolescent, irritability is a non-
speciﬁc clinical marker of a variety of disorders other
thanMDD.[5,6] However, scant empirical research exists
on the implications of including irritability as a symptom
of adult MDD.
A distinction must be made here between using irri-
tability as a severity marker or a subtyping distinction
among adults with DSM-IV MDD and using irritability
to expand the deﬁnition of major depression. Whereas
existing research suggests that irritability in MDD may
serve as a severitymarker in clinical samples[7,8] and have
possible value as a diagnostic subtyping symptom,[4,8]
we are unaware of previous evidence on the implica-
tions of allowing irritability to be used to expand the
deﬁnition of adult MDD. Revising adult MDD criteria
to include irritability might help offset some postulated
gender bias in depression measurement, as sociocultural
theories suggest that current diagnostic criteriamight be
insensitive to gender differences in affective expression
due to men manifesting depression less than women in
terms of sadness and loss of interest and more in terms
of irritability.[9,10] Such an artifactual decrease in the es-
timated prevalence of male depression, if it exists, would
be corrected by including irritability as an equivalent of
dysphoria and anhedonia in assessing adult depression.
Empirical support is generally lacking for this intuitive
notion of qualitative gender-related mood discrepan-
cies, as there are inconsistent clinical reports of no gen-
der differences in depressive irritability,[1,8, 11,12] a male
preponderance,[13] and a female preponderance.[2,7]
Community data are rare, but recent nonrepresenta-
tive samples using college undergraduates found a fe-
male preponderance of so-called “male depression,”
characterized as more instrumental and aggressive
symptoms.[14] Other research has suggested that depres-
sion among youngmales sometimes goes undetected be-
cause it manifests with irritability in the absence of re-
ported sadness.[15]
Given that idioms of distress vary culturally, it is im-
portant to include culturally diverse samples in studies
of irritability in depression.[16,17] In order to cast as wide
a net as possible in this regard, we examined data from
the World Mental Health (WMH) Surveys, a series of
community epidemiological surveys of mental disorders
carried out in 21 countries throughout theworld.[18] The
sample includes 110,729 adult respondents. We carried
out a preliminary analysis of the extent to which ex-
panding the list of Criterion A symptoms of DSM-IV
Depression and Anxiety
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adult MDD to include irritability and allowing irritabil-
ity to substitute for dysphoria and anhedonia as a core
symptomofMDDwould change prevalence estimates of
DSM-IV MDD. We also examined the extent to which
such changes would inﬂuence estimates of gender dif-
ferences in MDD and the severity of role impairment
associated with MDD. The analysis is preliminary in
that only a single question about persistent irritability
was included in the Composite International Diagnostic
Interview (CIDI) assessment of MDD, but results could
nonetheless be useful given that only limited information
from other sources exists on this issue.
MATERIALS AND METHODS
SAMPLE
The WMH surveys were conducted in 22 countries, including ﬁve
in countries classiﬁed by the World Bank[19] as low or lower-middle
income (national surveys in Colombia and Ukraine and regional sur-
veys in Nigeria [21 of 36 states] and the People’s Republic of China
[one in the Metropolitan Areas of Beijing and Shanghai and a second
in the Metropolitan Area of Shenzhen]), six in countries classiﬁed as
upper-middle income (national surveys in Bulgaria, Lebanon, Mexico,
Romania, and South Africa, and a regional survey in Brazil [Sao Paulo
Metropolitan Area]), and 11 in countries classiﬁed as high income (na-
tional surveys in Belgium, France, Germany, Israel, Italy, the Nether-
lands, New Zealand, Northern Ireland, Spain, and United States, and
a regional survey in Japan [11 Metropolitan Areas]; Table 1). Each of
the 22 surveys was administered to randomly selected respondents in a
probability sample of households representative of the population.[20]
Interviews were carried out face-to-face in the homes of respon-
dents. The 110,726 adult (age 18+) respondents who completed the
survey included 28,235 in low/lower-middle income countries, 25,666
in upper-middle income countries, and 56,825 in high income coun-
tries. Individual country samples ranged from a low of 2,357 (Romania)
to a high of 12,790 (NewZealand). Theweighted average response rate
across surveys was 71.4% (ranging from a low of 45.9% in France to
a high of 87.7% in Colombia). The sample data in each country were
weighted to adjust for discrepancies between the samples and popula-
tion census data on a range of demographic and geographic variables.
DIAGNOSTIC ASSESSMENT
Diagnoses were based on Version 3.0 of the World Health Orga-
nization CIDI,[21] a fully structured instrument designed for use by
trained lay interviewers. DSM-IV diagnostic criteria[22] were used in
making diagnoses. Organic exclusions and diagnostic hierarchy rules
were applied. The CIDI was developed in English and then trans-
lated, back translated, and harmonized in each country in collabora-
tion with theWMHData CollectionCoordinating Centre (DCCC) at
the University of Michigan in the United States. This was done using
an expanded version of the standard WHO translation protocol.[23]
Interviewers were trained by culturally competent bilingual (in En-
glish and the language(s) of the survey) supervisors in each country
using consistent interviewer training materials that were standardized
across surveys. Quality control protocols were also standardized and
audited by DCCC staff to check interviewer accuracy and specify data
cleaning and coding procedures.[24] The institutional review board of
the organization that coordinated the survey in each country approved
and monitored compliance with procedures for obtaining informed
consent and protecting human subjects.
The CIDI assesses a wide range of disorders including major de-
pressive episode, anxiety disorders (generalized anxiety disorder, panic
disorder, agoraphobia without panic disorder, speciﬁc phobia, social
phobia, posttraumatic stress disorder, adult separation anxiety disor-
der), intermittent explosive disorder, and substance use disorders (al-
cohol and drug abuse with or without dependence). The majority of
surveys also assessed bipolar spectrum disorder (BP-I, BP-II, and sub-
threshold bipolar disorder (BPD)), but the latter disorders were not
assessed in some of the initial WMH surveys. CIDI–SCID (where
SCID is Structured Clinical Interview for DSM-IV) concordance us-
ing a probability subsample of WMH survey respondents from four
countries found generally good concordance for these diagnoses.[25]
Worst lifetime episodes are the focus of assessment. Concordance of
diagnoses based on theCIDIwith independent clinical diagnoses based
on the SCID[26] was assessed in four WMH countries. Concordance
was found to be good for major depressive episode (MDE) (area under
the receiver operating characteristic curve (AUC) = 0.79), excellent
for bipolar spectrum disorder (AUC = 0.94), and generally good for
the other DSM-IV disorders assessed.[25]
The CIDI assessment of MDD includes several symptoms in ad-
dition to those speciﬁed in DSM-IV, including irritability, euphoria,
extreme irritability, andmultiple other hypomanic symptoms designed
to distinguish between depressive episodes andmixed episodes. Persis-
tent irritability is assessed with a simple yes–no query about whether
the respondent was “irritable, grouchy, or in a bad mood nearly every
day” during the worst 2 weeks of the index episode of sadness or anhe-
donia. It is possible to use responses to this question to determine how
much the estimated prevalence of MDD would increase if irritability
were used as an additional symptomofMDD. Speciﬁcally, respondents
who did not meet lifetime criteria for bipolar spectrum disorder but
who had exactly four of the requisite Criterion A symptoms of MDD
were reexamined to determine whether the addition of irritability to
the Criterion A symptom set would lead to a meaningful increase in
the number of respondents classiﬁed as having MDD using a revised
5+ of 10 (rather than the current 5+ of 9) rule. The exclusion of re-
spondents with a history of bipolar spectrum disorder (lifetime history
of BPD, subthreshold BPD, or core hypomanic symptoms) was made
based on the fact that depression with irritability could plausibly be
conceptualized as a BP spectrum disorder. As noted below, though,
BPD was not assessed in some countries, in which case this type of
irritable depression was presumably overestimated.
In addition, we were able to explore the implications of including
irritability as a core symptomofMDD (i.e. as a symptom that could sub-
stitute for dysphoria or anhedonia) in eight countries where a separate
assessment was made of all other symptoms of MDD during episodes
of being irritable among respondents who reported that they did not
experience either dysphoria or anhedonia during these episodes. This
assessment asked respondents whether they ever had episodes lasting
2 weeks or longer when they were “irritable, grumpy, or in a bad mood
most of the day nearly every day.” The requirement that this symptom
last “most of the day” was imposed because DSM-IV stipulates that ir-
ritability is a substitute for dysphoria among youth and the criterion for
dysphoric mood requires persistence most of the day nearly every day.
We classiﬁed respondents who reported such episodes as qualifying
for a deﬁnition of irritable depression if they additionally had four or
more of the remaining (i.e. exclusive of dysphoria and anhedonia) seven
Criterion A symptoms of MDD, again excluding respondents with a
history of bipolar spectrum disorder. The eight countries in which
this assessment was made included Colombia, Japan, Lebanon, Mex-
ico, Nigeria, PRC Beijing/Shanghai, Ukraine, and the United States.
A total of 43,153 respondents were included in the surveys in these
eight countries.
Respondents who met criteria either for DSM-IV MDD or irrita-
ble depression in the 12 months before interview were administered a
modiﬁed version of the Sheehan Disability Scales (SDS)[27] to assess
severity of the role impairment caused by their depression. The SDS
uses a 0–10 visual analogue scale with labels of none (0), mild (1–3),
Depression and Anxiety
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TABLE 1. World Mental Health (WMH) Survey sample characteristicsa
Surveyb Sample characteristicsc Field dates Age range Sample size Response rated
I. Low/lower-middle income countries
Colombia NSMH All urban areas of the
country (approximately
73% of the total national
population)
2003 18–65 (4,426) 87.7
Nigeria NSMHW 21 of the 36 states in the
country, representing
57% of the national
population. The surveys
were conducted in
Yoruba, Igbo, Hausa, and
Eﬁk languages.
2002–3 18+ (6,752) 79.3
PRC – Beijing/Shanghai B-WMH Beijing and Shanghai
metropolitan areas.
2002–3 18+ (5,201) 74.7
S-WMH
PRC – Shenzhen Shenzhen Shenzhen metropolitan
area. Included temporary
residents as well as
household residents.
2006–7 18+ (7,132) 80.0
Ukraine CMDPSD Nationally representative. 2002 18+ (4,724) 78.3
Total (28,235)
II. Upper-middle income countries
Brazil Sa˜o Paulo Megacity Sa˜o Paulo metropolitan
area.
2005–7 18+ (5,037) 81.3
Bulgaria NSHS Nationally representative. 2003–7 18+ (5,318) 72.0
Lebanon LEBANON Nationally representative. 2002–3 18+ (2,857) 70.0
Mexico M-NCS All urban areas of the
country (approximately
75% of the total national
population).
2001–2 18–65 (5,782) 76.6
Romania RMHS Nationally representative. 2005–6 18+ (2,357) 70.9
South Africa SASH Nationally representative. 2003–4 18+ (4,315) 87.1
Total (25,666)
III. High income countries
Belgium ESEMeD Nationally representative.
The sample was selected
from a national register of
Belgium residents
2001–2 18+ (2,419) 50.6
France ESEMeD Nationally representative.
The sample was selected
from a national list of
households with listed
telephone numbers.
2001–2 18+ (2,894) 45.9
Germany ESEMeD Nationally representative. 2002–3 18+ (3,555) 57.8
Israel NHS Nationally representative. 2002–4 21+ (4,859) 72.6
Italy ESEMeD Nationally representative.
The sample was selected
from municipality
resident registries.
2001–2 18+ (4,712) 71.3
Japan WMHJ2002–2006 Eleven metropolitan areas. 2002–6 20+ (4,129) 55.1
Netherlands ESEMeD Nationally representative.
The sample was selected
from municipal postal
registries.
2002–3 18+ (2,372) 56.4
moderate (4–6), severe (7–9), and very severe (10) to characterize severity
of impairment in each of four areas of living (work, homemanagement,
social life, close relationships). The SDS has excellent internal consis-
tency reliability[27–29] and good concordance with objective measures
of role functioning.[27–31]
ANALYSIS METHODS
Cross-tabulations estimated prevalence of irritable depression using
eachof the twodeﬁnitions described above aswell as relative prevalence
versus DSM-IV/CIDI MDD. Cross-tabulations also compared rates
of severe impairment assessed in the SDS of respondents with irritable
Depression and Anxiety
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TABLE 1. Continued
Surveyb Sample characteristicsc Field dates Age range Sample size Response rated
New Zealande NZMHS Nationally representative. 2003–4 18+ (12,790) 73.3
N. Ireland NISHS Nationally representative. 2004–7 18+ (4,340) 68.4
Spain ESEMeD Nationally representative. 2001–2 18+ (5,473) 78.6
United States NCS-R Nationally representative. 2002–3 18+ (9,282) 70.9
Total (56,825) 71.4
IV. Total (110,726)
aThe World Bank. (2008). Data and Statistics. Accessed May 12, 2009. Available at: http://go.worldbank.org/D7SN0B8YU0
bNSMH (The Colombian National Study of Mental Health); IMHS (Iraq Mental Health Survey); NSMHW (The Nigerian Survey of Mental
Health and Wellbeing); B-WMH (The Beijing World Mental Health Survey); S-WMH (The Shanghai World Mental Health Survey); CMDPSD
(Comorbid Mental Disorders during Periods of Social Disruption); NSHS (Bulgaria National Survey of Health and Stress); LEBANON (Lebanese
Evaluation of the Burden of Ailments and Needs of the Nation); M-NCS (The Mexico National Comorbidity Survey); RMHS (Romania Mental
Health Survey); SASH (South Africa Health Survey); ESEMeD (The European Study Of The Epidemiology Of Mental Disorders); NHS (Israel
National Health Survey); WMHJ2002–2006 (World Mental Health Japan Survey); NZMHS (New Zealand Mental Health Survey); NISHS
(Northern Ireland Study of Health and Stress); NMHS (Portugal National Mental Health Survey); NCS-R (The US National Comorbidity Survey
Replication).
cMostWMH surveys are based on stratiﬁedmultistage clustered area probability household samples in which samples of areas equivalent to counties
or municipalities in the United States were selected in the ﬁrst stage followed by one or more subsequent stages of geographic sampling (e.g. towns
within counties, blocks within towns, households within blocks) to arrive at a sample of households, in each of which a listing of household members
was created and one or two people were selected from this listing to be interviewed. No substitution was allowed when the originally sampled
household resident could not be interviewed. These household samples were selected from Census area data in all countries other than France
(where telephone directories were used to select households) and the Netherlands (where postal registries were used to select households). Several
WMH surveys (Belgium, Germany, Italy) used municipal resident registries to select respondents without listing households. The Japanese sample
is the only totally unclustered sample, with households randomly selected in each of the 11 metropolitan areas and one random respondent selected
in each sample household. Of the 22 surveys, 15 are based on nationally representative household samples.
dThe response rate is calculated as the ratio of the number of households in which an interview was completed to the number of households
originally sampled, excluding from the denominator households known not to be eligible either because of being vacant at the time of initial contact
or because the residents were unable to speak the designated languages of the survey. The weighted average response rate is 71.4%.
eNew Zealand interviewed respondents 16+ but for the purposes of cross-national comparisons, we limit the sample to those 18+.
depression and DSM-IV/CIDI MDD. Retrospective disorder age-of-
onset reports were analyzed to estimate differential predictors of life-
time risk of irritable depression and DSM-IV/CIDI MDD in discrete
time survival models with person–year the unit of analysis and a logistic
link function.[32] Coefﬁcients were exponentiated and reported as odds
ratios (ORs) and 95% conﬁdence intervals. Standard errors of all de-
scriptive statistics were estimated using the Taylor series linearization
method[33] in SAS version 9.3[34] to adjust for the weighting and clus-
tering of WMH data. Multivariate signiﬁcance of predictor sets was
evaluated using Wald χ2 tests based on design-corrected coefﬁcient
variance–covariance matrices. Statistical signiﬁcance was consistently
evaluated using two-sided 0.05-level tests.
RESULTS
PREVALENCE USING THE 5+ OF 10 RULE
Including irritability as an additional Criterion A
symptom of MDD and using a 5+ of 10 rule instead
of a 5+ of 9 rule increases the estimated lifetime preva-
lence of MDD by an average of 0.4% across all surveys,
from 11.2 to 11.6%. (Table 2) This increase represents
a 3.5% proportional increase over the base (i.e. 0.4/11.6
= 3.5%). The range of prevalence estimates using this
deﬁnition across surveys is 0.0–1.0% (1.0–9.2% propor-
tional increase) and the interquartile range (IQR; i.e.
25th–75th percentiles) is 0.2–0.6% (2.8–5.4% propor-
tional increase). It should be noted that the three sur-
veys with the highest prevalence estimates (0.9–1.0%)
are among those that did not assess bipolar disorder.
This means that the prevalence estimate of irritable de-
pression is anticonservative in these countries.
The pooled average prevalence estimate across sur-
veys is very similar for women (0.5%) and men (0.4%)
and the gender difference is not signiﬁcant either in any
individual survey (t= 0.0–1.8,P = .08–.93) or in the total
sample pooled across surveys (t= 1.8,P= .07).However,
given that women consistently have a higher prevalence
of DSM-IV MDD than men,[35] the proportional in-
crease in total depression prevalence is for the most part
(16 of 22 surveys) higher among men than women, with
median (IQR) proportional increases of 5.6% (2.7–6.6)
among men and 3.3% (2.2–4.3) among women. These
gender differences in proportional increase are signif-
icant at the .05 level in six surveys (Nigeria, Ukraine,
Mexico, Sao Paulo, Belgium, Netherlands).
PREVALENCE USING IRRITABILITY AS AN
EQUIVALENT OF DYSPHORIA AND ANHEDONIA
As noted above, eight of the WMH surveys included
a separate interview section that screened for lifetime
episodes of irritability lasting most of the day nearly ev-
ery day for 2 weeks or longer, including an assessment
of all other symptoms of DSM-IV MDD during those
Depression and Anxiety
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TABLE 3. Estimated lifetime prevalence of irritable depression based on using irritability as an equivalent of dysphoria
or anhedoniab
Irritable depression/total depressionc Broadly deﬁned irritable
Irritable depression total depressionc depression/total depressiond
Total Male Female Total Male Female Total Male Female
% (SE) % (SE) % (SE) % (SE) % (SE) % (SE) % (SE) % (SE) % (SE)
I. Low/lower-middle income countries
Colombia 0.2 (0.1) 0.2 (0.1) 0.1 (0.1) 1.0 (0.4) 1.7 (1.0) 0.7 (0.3) 4.0 (1.3) 3.8 (1.5) 4.2 (1.8)
Nigeria 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 2.4 (1.4) 5.3 (1.1) 0.0 (0.0)
PRC Beijing/Shanghai 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 4.3 (1.5) 4.3 (1.3) 4.3 (2.5) 5.2 (1.5) 4.3 (1.3) 6.5 (2.8)
Ukraine 0.1 (0.1) 0.1 (0.1) 0.1 (0.1) 0.6 (0.3) 1.2 (0.9) 0.3 (0.2) 6.6 (1.0) 9.7a (2.1) 5.4 (0.8)
II. Upper-middle income countries
Lebanon 0.3 (0.1) 0.2 (0.2) 0.4 (0.1) 2.2 (0.9) 1.9 (1.9) 2.3 (0.8) 7.5 (1.2) 8.4 (3.1) 7.0 (1.6)
Mexico 0.2 (0.1) 0.2 (0.2) 0.2 (0.1) 2.0 (1.0) 2.8 (0.2) 1.7 (0.6) 5.1 (1.3) 7.8 (0.8) 3.8 (0.9)
III. High income countries
Japan 0.4 (0.1) 0.4 (0.1) 0.5 (0.2) 5.9 (1.4) 7.9 (2.7) 5.0 (1.5) 9.6 (1.8) 13.1 (3.2) 8.1 (1.9)
United States 0.4 (0.1) 0.3 (0.1) 0.5 (0.1) 2.4 (0.4) 2.7 (0.7) 2.2 (0.3) 5.1 (0.6) 5.6 (0.9) 4.8 (0.7)
IV. Total 0.2 (0.0) 0.2 (0.0) 0.3 (0.0) 2.1 (0.2) 2.6 (0.4) 1.8 (0.2) 5.5 (0.4) 6.6 (0.6) 5.0 (0.4)
aSigniﬁcant gender difference at the .05 level, two-sided test.
bRespondents with a lifetime history of bipolar spectrum disorder were excluded from the analysis. See the text for a full description.
cThe proportional increase in the estimated lifetime prevalence of depression if irritable depression was included along with DSM-IV/CIDI MDD.
dThe proportional increase in the estimated lifetime prevalence of depression if both types of irritable depression (i.e. the type based on using the 5+
of 10 symptoms rule and the type based on using irritability as an equivalent of dysphoria or anhedonia) were included along with DSM-IV/CIDI
MDD.
episodes of persistent irritability (Table 3). The mean
lifetime prevalence estimate of irritable depression us-
ing the requirement of irritability plus four or more
additional symptoms is 0.2% and the range (IQR) is 0.0–
0.4% (0.2–0.3%), representing a proportional increase
over the expanded (to include irritable depression using
the 5+ of 10 rule) base of 2.1% (2.2–2.4%).
The pooled average prevalence estimate across sur-
veys is very similar for women (0.3%) and men (0.2%),
and the gender difference is not signiﬁcant either in any
individual survey (t = 0.0–1.6,P = .11–.90) or in the total
sample pooled across surveys (t= 1.1,P= .26).However,
as with the deﬁnition based on the 5+ of 10 symptom
rule, the proportional increase in total depression due to
the inclusion of this second type of irritable depression is
somewhat higher amongmen than women, with median
(IQR) proportional prevalence increases of 2.3% (1.7–
2.8%) amongmen and 1.9% (0.7–2.3%) among women.
This gender difference is not signiﬁcant, though, in any
of the surveys.
PREVALENCE COMBINING THE TWO
DEFINITIONS
When we combine the two deﬁnitions of irritable de-
pression, the pooled proportional mean (IQR) increase
in the estimated lifetime prevalence of total major de-
pression over the DSM-IV deﬁnition of MDD is 5.5%
(5.1–6.0%) in the total sample, 6.6% (5.3–8.4%) among
men, and 5.0% (4.2–6.5%) among women. The gender
difference is insigniﬁcant (t = 1.8, P = 0.07).
SUBGROUP DIFFERENCES
In addition to gender differences, we examined the
possibility that relative prevalence of irritable depres-
sion compared to DSM-IV/CIDI MDD varies by age,
education, and country income level. We also examined
gender, age, and education differences by country in-
come level. In analyses pooled across all samples, the
lower relative prevalence of irritable depression among
women than men was found to be signiﬁcant in high in-
come (χ21 = 10.8, P < .001) and upper-middle income
(χ21 = 6.5, P = .011) but not low/lower-middle income
(χ21 = 0.6, P = .45) countries (Table 4). Age differences
in relative prevalence were insigniﬁcant overall (χ23 =
6.6,P= .08) as well as in surveys carried out in each of the
three country income groups (χ23 = 2.0–7.8, P = .052–
.57), but with a trend toward higher relative prevalence
among the youngest (ages 18–29) respondents. Differ-
ences by education were also insigniﬁcant overall (χ23 =
6.3, P = .10) as well as in surveys carried out in each of
the country income groups (χ23 = 3.8–7.1, P = .07–.28).
Differences by country income level, ﬁnally, were close
to signiﬁcant (χ22 = 5.8, P = .054) due to higher rela-
tive prevalence of irritable depression in low and middle
income countries than in high income countries. Even
in the subsample with the highest relative prevalence
(youngmen in low ormiddle income countries), though,
themarginal increase in broadly deﬁned lifetime depres-
sion was less than 7%.
IMPAIRMENTS IN ROLE FUNCTIONING IN
IRRITABLE DEPRESSION VERSUS MDD
Role impairment was assessed only for 12-month
cases. Severe role impairment in at least one SDS role
domain was reported by a signiﬁcantly lower propor-
tion of respondents with irritable depression thanDSM-
IV/CIDI MDD in the total sample (18.9 versus 43.3%,
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TABLE 4. Subsample differences in relative lifetime prevalence of irritable depression versus DSM-IV/CIDI MDD
Country income level
Total High Upper-middle Low/lower-middle
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Gender
Female 0.6a (0.5–0.8) 0.6a (0.5–0.8) 0.5a (0.3–0.9) 0.8 (0.5–1.3)
Male 1.0 – 1.0 – 1.0 – 1.0 –
χ21 16.2a 10.8a 6.5a 0.6
Age
60+ 0.8 (0.6–1.0) 1.0 (0.6–1.6) 0.4a (0.2–0.8) 0.8 (0.4–1.5)
45–59 0.7a (0.5–0.9) 0.7 (0.5–1.0) 0.8 (0.4–1.5) 0.7 (0.4–1.2)
30–44 0.8 (0.6–1.1) 0.8 (0.6–1.2) 0.8 (0.5–1.3) 0.9 (0.5–1.6)
18–29 1.0 – 1.0 – 1.0 – 1.0 –
χ23 6.6 3.8 7.8 2.0
Educationb
High 1.1 (0.8–1.6) 1.4 (1.0–2.1) 0.6 (0.2–1.4) 1.1 (0.6–2.4)
High-average 0.8 (0.5–1.1) 1.0 (0.6–1.4) 0.5 (0.2–1.1) 0.4a (0.2–1.0)
Low-average 1.0 (0.7–1.3) 1.1 (0.7–1.7) 0.5 (0.3–1.0) 1.0 (0.6–1.9)
Low 1.0 – 1.0 – 1.0 – 1.0 –






(n) (110,726) (56,825) (25,666) (28,235)
aSigniﬁcant difference in the relative prevalence of irritable depression versus DSM-IV/CIDI MDD at the .05 level, two-sided test.
bGiven the existence of substantial cross-national differences in educational attainment, respondents were divided roughly into quartiles in each
country on the basis of level of education and pooled across countries in these categories rather than in terms of absolute number of years of
education.
t= 14.1,P< .001). (Results not shownbut available upon
request.) Relative odds of severe role impairment in lo-
gistic regression models controlling for age, gender, ed-
ucation, and countrywere also signiﬁcantly lower among
respondents with irritable depression versus MDD and
relatively consistent across the four SDS domains (OR=
0.2–0.4 across SDS role domains and 0.3 overall). Very
similar patterns were found in subsamples deﬁned by
country income level, with ORs in the range 0.3–0.4 in
low/lower-middle income countries, 0.3.–0.5 in upper-
middle income countries, and 0.1–0.4 in high income
countries (Table 5). More detailed analyses failed to ﬁnd
evidence of signiﬁcant differences in these relative-odds
based on respondent age (χ23 = 2.0–6.1, P = .11–.57),
gender (χ21 = 0.3–3.0, P = .09–.59), or education (χ23 =
1.8–4.9, P = .18–.61). Based on these low rates of sever-
ity, the proportion of severe broadly deﬁned cases due to
irritable depression (2.1%) is even smaller than the pro-
portion of overall broadly deﬁned cases due to irritable
depression (7.0%).
DISCUSSION
Although these results are limited by the use of a
fully structured lay-administered diagnostic interview,
the good concordance foundbetweendiagnoses basedon
the CIDI and clinical diagnoses based on blinded SCID
interviews is reassuring.[25] The fact that irritability was
assessed using only a single question in the MDD sec-
tion about being “irritable, grouchy, or in a bad mood,”
though, possibly led to underreporting of true irritabil-
ity, might have obscured important distinctions in types
of irritability,[36,37] and could have also introduced false
positives due to the ambiguity of the term “bad mood.”
The fact that quite a few surveys did not assess bipolar
disorder could have added to the false-positive problem
in leading respondents with bipolar disorder to be clas-
siﬁed incorrectly as having irritable depression.
These limitations notwithstanding, our results show
clearly that only a very small proportion of the popula-
tions in the countries studied ever meets criteria for a
diagnosis of irritable depression in the absence of life-
time DSM-IV MDD. Furthermore, our ﬁnding that
the prevalence of irritable depression in the absence of
DSM-IV MDD does not differ markedly between men
and women is inconsistent with sociocultural theories
regarding irritability as a possible male equivalent of
depression.[9,10,13] We found some evidence that irri-
table depression is more common relative to DSM-IV
MDD among young men in low and middle income
countries, but even in this segment of the population,
there were fewer than seven cases of lifetime irritable de-
pression for every 93 cases of lifetime DSM-IV MDD.
It is certainly possible that other symptoms differentiate
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TABLE 5. Severe role impairments due to 12-month irritable depressionb versus 12-month DSM-IV/CIDI MDDc
Irritable depression DSM-IV/CIDI MDD
% (SE) % (SE) OR (95% CI)
I. Total sample
Work 7.8a (1.1) 23.7 (0.6) 0.3a (0.1–0.5)
Home management 6.1a (1.4) 25.1 (0.7) 0.2a (0.1–0.4)
Social life 11.3a (1.4) 27.8 (0.7) 0.3a (0.2–0.5)
Close relationships 12.4a (1.4) 24.2 (0.6) 0.4a (0.3–0.6)
(n) (230) (5,376) (5,606)
II. Low/lower-middle income countries
Work 6.0a (3.0) 15.6 (1.3) 0.3 (0.1–1.0)
Home management 7.2a (2.9) 20.9 (1.3) 0.3a (0.1–0.7)
Social life 7.8a (2.3) 16.3 (1.2) 0.4a (0.2–1.0)
Close relationships 9.6a (2.4) 17.8 (1.3) 0.4a (0.2–1.0)
(n) (59) (1,065) (1,124)
III. Upper-middle income countries
Work 13.5a (3.3) 28.4 (1.7) 0.4 (0.1–1.3)
Home management 8.4a (3.8) 29.1 (1.5) 0.3a (0.1–0.8)
Social life 20.2a (3.9) 32.7 (1.5) 0.5 (0.3–1.0)
Close relationships 18.4a (3.9) 30.7 (1.6) 0.5 (0.3–1.0)
(n) (56) (1,267) (1,323)
IV. High income countries
Work 5.4a (0.2) 24.6 (0.8) 0.2a (0.1–0.5)
Home management 4.5a (1.1) 25.0 (0.9) 0.1a (0.1–0.4)
Social life 7.9a (1.5) 29.9 (0.9) 0.2a (0.1–0.4)
Close relationships 10.3a (1.7) 23.8 (0.8) 0.4 (0.2–0.7)
(n) (115) (3,044) (3,159)
aSigniﬁcant difference between irritable depression and DSM-IV/CIDI MDD in the percentage of cases with severe role impairment.
bIrritable depression was deﬁned broadly to include both the type based on using the 5+ of 10 symptoms rule and, in the eight surveys that included
a separate interview section on episodes of persistent irritability, the type based on using irritability as an equivalent of dysphoria or anhedonia.
cBased on a logistic regression model with a dummy predictor variable for irritable depression (coded 1) versus DSM-IV/CIDI MDD (coded 0)
predicting a dichotomous outcome for severity of role impairment controlling for respondent age, gender, education, and country.
male from female depression that need to be elucidated
in future research, but the results presented here are in-
consistent with the notion that irritability is central to
such differences.
We also found that irritable depression is associated
with substantially less role impairment than DSM-IV
MDD, resulting in there being only about two cases of
severely impairing lifetime irritable depression for every
98 cases of severely impairing lifetime DSM-IV MDD.
One possible explanation for this ﬁnding of lower levels
of severe impairment in irritable depression than DSM-
IV depressionmight be that the cases of irritable depres-
sionmight include a high proportion of respondentswho
met all criteria for mania or hypomania other than the
requirement for marked impairment in mania (DSM-IV
Criterion D) or clinically signiﬁcant impairment in hy-
pomania (DSM-IV Criterion E). This was not the case,
though, as such cases were removed from the analysis
at the onset when we excluded respondents with core
hypomanic symptoms in an effort to avoid this kind of
confounding.
It is noteworthy that despite the very small number
of respondents who met criteria for irritable depression
in the absence of DSM-IV MDD, a majority of WMH
respondents with a history of MDD report irritability
during their depressive episodes.[35] This is consistent
with the ﬁnding in numerous clinical studies that a high
proportion of adult patients in treatment for MDD have
symptoms of irritability.[2,5–7,38–41] It also ties in with the
pointmade in the introduction that irritabilitymight be a
useful severity marker[7,8] or a useful basis for subtyping
adults with DSM-IV MDD[4,8] even if it is not a useful
basis for expanding the deﬁnition of MDD. It might be
the case that information about irritability has relevance
for depression treatment. In interpreting the results of
our study, it is important to be clear that we are address-
ing only the issue of expanding the deﬁnition of MDD
and not issues of subtyping or distinguishing the severity
of threshold cases of MDD.
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